Clinical trials: Breast Cancer (Early Breast Cancer)
Non Hodgkin Lymphoma, Breast Cancer
Patient Preference for Pegfilgrastim (Neulasta®) Application Forms
The study aims to compare two application forms (pre-filled syringe and On-body injector) of the same active drug (pegfilgrastim) in adult patients under chemotherapy regarding patient preference and health economics.
- Trial name
- CONVENIENCE (NCT03619993)
- Testing
- On-body injector, Pre-filled syringe
- Where
- 48 sites in Germany
- Volunteers
- 404 people
- Sponsor
- iOMEDICO AG
Early Breast Cancer
The Prognostic Role of TILs and CD8+ T Cells in Operable Breast Cancer
T cells are a broad class of adaptive immune cells, while CD8⁺ T cells are a specific, specialized subset of T cells, defined by the presence of the CD8 surface receptor.
- Trial name
- Ν/Α (NCT07545434)
- Where
- Greece
- Volunteers
- 3,646 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Neoplasms
Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen \& are switched to Aromasin®…
- Trial name
- NCT01176916
- Testing
- Aromasin (exemestane)
- Where
- 53 sites in China
- Volunteers
- 564 people
- Sponsor
- Pfizer
Breast Cancer, Fatigue
Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment
Many patients receiving radiation therapy for breast cancer experience fatigue although doctors do not fully understand why. The purpose of this study is to test if patients who experience fatigue during radiation treatment for…
- Trial name
- NCT02836093
- Testing
- FACIT-Fatigue 52-point questionnaire
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Solid Tumor
Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
DNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict…
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Lung Neoplasms
- Trial name
- METHYLSCAPE-CO (NCT07741435)
- Testing
- Methylscape DNA methylation assay
- Where
- Colombia
- Volunteers
- 3,250 people, healthy volunteers welcome
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Early-stage Breast Cancer
Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
REaCT ZOL will compare one 4 mg dose of Zoledronate vs. one 4 mg dose of Zoledronate given every 6 months for 3 years.
- Trial name
- REaCT-ZOL (NCT03664687)
- Testing
- Zoledronate
- Where
- 6 sites in Canada
- Volunteers
- 211 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal…
- Trial name
- NCT00093002
- Testing
- Fulvestrant
- Where
- 31 sites in United States, Austria and 4 more
- Volunteers
- 179 people
- Sponsor
- AstraZeneca
Breast Cancer
Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery
The purpose of this study is to determine if this combination is safe and effective in this situation especially to increase the rate of pathological complete response (PCR).
- Trial name
- NCT00251329
- Testing
- neoadjuvant chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Cancer Research Network
Breast Cancer
Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- GIM4 (NCT01064635)
- Testing
- Letrozole
- Where
- Italy
- Volunteers
- 2,056 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.
- Trial name
- Ax-003 (NCT00638391)
- Testing
- Anastrozole
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Breast Cancer, Premenopausal Breast Cancer
Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer
Although combination endocrine therapy has been associated with significant reduction in risk of recurrence in younger women with hormone receptor positive breast cancer, it has been associated with more adverse effects and…
- Conditions
- Breast Cancer, Premenopausal Breast Cancer, Hormone Receptor Positive Tumor
- Trial name
- MyCHOICE (NCT03407768)
- Testing
- Individualized interventions
- Where
- 2 sites in Canada
- Volunteers
- 41 people
- Sponsor
- University of Saskatchewan
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT05929768
- Testing
- Biospecimen Collection, Carboplatin, Cyclophosphamide
- Where
- 963 sites in United States, Mexico and 1 more
- Volunteers
- 2,400 people
- Sponsor
- SWOG Cancer Research Network
Early-stage Breast Cancer
Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients
Primarily, this clinical investigation compared the efficacy of tamoxifen + aminoglutethimide vs. tamoxifen alone in terms of prognosis (overall survival) in postmenopausal patients with potentially curative, operated hormone…
- Trial name
- NCT00309491
- Testing
- Tamoxifen alone, Tamoxifen + Aminoglutethimide
- Volunteers
- 2,021 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Triple -Negative Breast Cancer
Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer
Eligible patients was assigned in a 1:1 ratio to receive either low-dose capecitabine maintenance (intervention group) which is newly diagnostic to be planned to receive capecitabine after finishing the standard adjuvant…
- Trial name
- NCT07143097
- Testing
- capecitabine
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Beni-Suef University
Breast Cancer
An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment
The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postmenopausal women with early…
- Trial name
- NCT00737009
- Where
- 3 sites in Vietnam
- Volunteers
- 259 people
- Sponsor
- AstraZeneca
Breast Cancer, ER-positive Breast Cancer
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
The majority of patients (pts) with breast cancer have hormone receptor positive (HR+) disease, and this holds true for pts with advanced breast cancer (ABC).
- Conditions
- Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT05826964
- Testing
- AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Miami
Breast Cancer
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Patients will be treated in a dose escalation scheme to investigate a role for the addition of a statin in the treatment of estrogen receptor positive breast cancer. Patients will take oral rosuvastatin daily.
- Trial name
- NCT02483871
- Testing
- Rosuvastatin
- Where
- United States
- Sponsor
- Duke University
Breast Cancer
Phase II Study of Single Agent Lenvatinib
The Investigators hypothesize that single agent lenvatinib has biological activity in estrogen receptor positive breast cancer, and that the effects are more pronounced in patients with positive RET expression in the tumor.
- Trial name
- NCT03168074
- Testing
- lenvatinib
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Early Stage Breast Cancer
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Primarily, this clinical investigation compared overall survival and recurrence-free survival in patients with hormone receptor-negative breast cancer treated with pre- and postoperative chemotherapy vs.
- Trial name
- NCT00309569
- Testing
- Cyclophosphamide, Methotrexate, Fluorouracil
- Volunteers
- 429 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Cancer Exercise: Evaluation of a Mobile App in Breast Cancer Survivors
This study will examine whether a mobile app increases exercise levels in breast cancer survivors after treatments, reduces fatigue, and improves physical functions.
- Trial name
- NCT06791018
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- University of Alberta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.